Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes

AIMS: Iron overload adversely affects patients with myelodysplastic syndromes (MDS), but benefits of iron chelation therapy have not been clearly demonstrated. We examined the association between deferasirox (DFX) therapy and mortality in transfusion-receiving Medicare patients. PATIENTS & METHO...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Comp Eff Res
Hlavní autoři: Zeidan, Amer M, Hendrick, Franklin, Friedmann, Erika, Baer, Maria R, Gore, Steven D, Sasane, Medha, Paley, Carole, Davidoff, Amy J
Médium: Artigo
Jazyk:Inglês
Vydáno: Future Medicine Ltd 2015
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5549705/
https://ncbi.nlm.nih.gov/pubmed/26274794
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/cer.15.20
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky